A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use

NCT07446439 · Recruiting

Last updated 2026-05-28

This clinical trial is testing whether tradipitant can reduce nausea and vomiting caused by GLP-1 receptor agonist medications in adults with obesity.

Status Recruiting Currently enrolling participants.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 280 people Planned (estimated).

Who can join Ages 18–65 · all sexes Healthy volunteers accepted.

Timeline Started 2026-03 · est. completion 2026-12

Where 10 sites · United States

What this study is testing ClinicalTrials.gov NCT07446439 ↗

Description as written by the study sponsor.

The goal of this study is to measure the effects of using Tradipitant to treat nausea and vomiting induced by GLP-1R agonist use in adults with class I or class II obesity, or adults who are overweight with at least one weight-related condition. The study is placebo-controlled with two treatment arms.

Treatments tested

Tradipitant also known as Nereus, VLY-686 Drug

Oral Capsule
Placebo Drug

Oral Capsule

Main thing measured	Proportion of participants with at least 1 vomiting episode per week in the tradipitant group compared to the placebo group as measured by a daily symptom diary.
Sponsor	Vanda Pharmaceuticals
Conditions studied	Nausea and Vomiting, Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07446439 ↗